Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 5kWORD 18k
12 March 2018
Question for written answer P-001516-18
to the Commission
Rule 130
Soledad Cabezón Ruiz (S&D)

 Subject:  The EU in USTR Special Report 301/2018
 Answer in writing 

Recently, the associations PhRMA and BIO which represent the main innovative undertakings in the field of biopharmaceutics in the US and which act as pharmaceutical pressure groups, asked the office of the US Trade Representative (USTR) to include the EU in its Special Report 301/2018.

The report annually reviews the implementation of intellectual property rights (IP) in other countries and is used as a means to put pressure on countries to comply with US requirements on IP for the benefit of its industry.

The reason for the request is the ongoing review, by the European Commission, of existing incentives related to IP for the biopharmaceutical industry, and their impact on innovation and access to medicines. In the request, PhRMA and its members encourage the US government to promote robust protection of IP in the EU and its Member States and call on the US government to seek guarantees that the review will not result in measures that weaken the protection of IP.

What measures in response to these pressures has the Commission planned to take in order to ensure the objectivity and impartiality of the report?

Original language of question: ES 
Last updated: 14 March 2018Legal notice